STAT
FEBRUARY 28, 2024
“The mindset of Big Pharma in those days was one pill for millions and millions of people,” said John LaMattina, who led Pfizer’s research division from 1999 to 2007. “Everyone was looking for the next Lipitor, and when that fizzled out, there was an exodus out of psychotherapeutic areas.”
pharmaphorum
DECEMBER 21, 2021
During the course of the webinar, Keefer explained how specialty sites, with deep knowledge on one or certain groups of Rare Diseases, are crucial for further progress in drug development to progress the number of treatments available to Rare Disease patients and to provide support to those individuals.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
pharmaphorum
DECEMBER 10, 2020
Oxford-based Sensyne uses patient data to improve drug development, disease understanding and clinical trial design, as well as to discover new drug targets, and also develops digital health software applications powered by AI such as GDm-Health for diabetes and CVm-Health for COVID-19. It already has access to around 6.1
European Pharmaceutical Review
SEPTEMBER 14, 2023
In 2001 and 2007, through 2009, the economy was hit hard. There was a significant slowdown in drug development, clinical trials, and new drugs coming to market. EMA prepares for winter antibiotic shortages That slowdown resulted in 211 drug shortages in 2010—the highest number recorded in a single year at the time.
European Pharmaceutical Review
JULY 25, 2023
Consistent methods must be employed across organisations to facilitate regulatory approvals, but this is a process that can hinder drug development. Digital technologies will be the driving force behind Lab of the Future, enabling greater pre-competitive collaboration and accelerated drug development pipelines.
pharmaphorum
APRIL 11, 2022
Dudley Tabakin, CEO of VivoSense, describes how this financing is set to accelerate the development of novel digital biomarkers and improve digital clinical outcome assessments. VivoSense software is developed specifically for analysis of data from wearable sensors”, explains Tabakin. “The
Pharmaceutical Technology
AUGUST 17, 2008
NB: Recent figures show the pharmaceutical industry spent $168m lobbying congress in 2007, how successful were the industry’s efforts and what are the main administration issues concerning the industry at present? ASL: The FDA’s purview is quite a bit broader than just drug development.
Expert insights. Personalized for you.
359 
Let's personalize your content